Martin Swarbrick

Martin obtained a BSc and PhD in chemistry from the University of Sheffield, UK, and carried out post-doctoral research at the University of Montreal, Canada. He returned to the UK to take up a role in industrial drug discovery and development at GlaxoSmithKline, where he went on to lead medicinal chemistry teams and discovery projects. In 2008, Martin joined CRUK’s Therapeutic Discovery Laboratories (CRUK-TDL) where, until recently, he led the medicinal chemistry, DMPK, protein sciences and structural biology functions. In June 2021 Martin joined Ryvu Therapeutics as Director of R&D Chemistry.